REG - Johnson Matthey PLC - Johnson Matthey completion of Health sale

Johnson MattheyAnnouncement

01/06/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4645Na&default-theme=true

RNS Number : 4645N  Johnson Matthey PLC  01 June 2022

Johnson Matthey announces completion of Health sale
1 June 2022

 

 

Johnson Matthey Plc (JM), a global leader in sustainable technologies, today
announces that that it has completed the sale of its Health business in
accordance with the terms of the sale agreement entered into between JM and
Altaris Capital Partners ("Altaris"), a leading healthcare investment firm.

The Health business, which has been rebranded as Veranova, was sold for a
total consideration of £325 million. As part of the transaction, JM will
retain approximately a 30% equity stake in Veranova.

 

ENDS

Johnson Matthey is a global leader in sustainable technologies that enable a
cleaner and healthier world. With over 200 years of sustained commitment to
innovation and technological breakthroughs, we improve the performance,
function and safety of our customers' products. Our science has a global
impact in areas such as low emission transport, energy, chemical processing
and making the most efficient use of the planet's natural resources. Today
about 15,000 Johnson Matthey professionals collaborate with our network of
customers and partners to make a real difference to the world around us. For
more information, visit www.matthey.com (http://www.matthey.com)

Inspiring science, enhancing life

 

For further information

 

Media

jmpr@matthey.com

0207 269 8001

Investor Relations

Martin Dunwoodie     Director of Investor
Relations                  0207 269 8241

Louise Curran           Senior Investor Relations Manager
0207 269 8235

Carla Fabiano           Senior Investor Relations Manager
0207 269 8004

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISABMFTMTTJBIT